THE EFFECT OF INCREASING THE TREATMENT TIME BEYOND 3 WEEKS ON THE CONTROL OF T2 AND T3 LARYNGEAL-CANCER USING RADIOTHERAPY

被引:84
|
作者
SLEVIN, NJ
HENDRY, JH
ROBERTS, SA
AGRENCRONQVIST, A
机构
[1] CHRISTIE HOSP & HOLT RADIUM INST,CANC RES CAMPAIGN,DEPT RADIOTHERAPY,MANCHESTER M20 9BX,LANCS,ENGLAND
[2] CHRISTIE HOSP TRUST,NATL HLTH SERV,DEPT EXPTL RADIAT ONCOL,MANCHESTER M20 9BX,ENGLAND
[3] CHRISTIE HOSP,NATL HLTH SERV,PATERSON INST CANC RES,DEPT BIOMATH & COMP,MANCHESTER M20 9BX,ENGLAND
关键词
TREATMENT TIME; T2 AND T3; CONTROL OF LARYNGEAL CANCER;
D O I
10.1016/0167-8140(92)90226-K
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Local control of cancer by radiotherapy may be prejudiced by accelerated tumour clonogen repopulation particularly during protracted treatment schedules. A series of 496 cases of T2 and T3 larynx cancer treated here by radiotherapy has been studied to examine the impact on local control of treatment durations ranging from 9 to 41 days. Data were analysed using a linear-quadratic formulation describing the fractionation sensitivity, with the incorporation of a parameter relating to treatment time. Using combined T2 and T3 data, the increase in dose required to maintain a constant local control (the time factor) was between 0.5 and 0.6 Gy per day. These values are similar to those reported for 4 weeks or more in the literature. Also, the calculated dose to control 50% of tumours, given over the standard Christie duration of 21 days, was on the line projected back from literature data over 28-66 days. The present data are consistent with the presence of such a time factor following a lag phase of not more than 3 weeks after starting radiotherapy. Hence, further consideration should be given to using shorter overall treatment times in radiotherapy for head and neck cancer.
引用
收藏
页码:215 / 220
页数:6
相关论文
共 50 条
  • [41] Machine learning model to preoperatively predict T2/T3 staging of laryngeal and hypopharyngeal cancer based on the CT radiomic signature
    Liu, Qianhan
    Liu, Shengdan
    Mao, Yu
    Kang, Xuefeng
    Yu, Mingling
    Chen, Guangxiang
    EUROPEAN RADIOLOGY, 2024, 34 (8) : 5349 - 5359
  • [42] CHANGES IN HEPATOCYTE METABOLISM OF 3,3'-T2 IN THE LOW T3 SYNDROME
    OTTEN, MH
    HENNEMANN, G
    DOCTER, R
    VISSER, TJ
    NETHERLANDS JOURNAL OF MEDICINE, 1982, 25 (06): : 175 - 176
  • [43] DEIODINATION OF INJECTED T3, RT3 AND 3',5'-T2 IN MAN
    GRUSSENDORF, M
    HUFNER, M
    ACTA ENDOCRINOLOGICA, 1981, 97 : 173 - 173
  • [44] Adjacent lobe invasion of T2 tumor in non-small cell lung cancer has T3 disease-like survival fissure invasion: T2 or T3?
    Ahmet Ucvet
    Serkan Yazgan
    Bahar Agaoglu Sanli
    Esra Yamansavci Sirzai
    Updates in Surgery, 2023, 75 : 2017 - 2025
  • [45] Adjacent lobe invasion of T2 tumor in non-small cell lung cancer has T3 disease-like survival fissure invasion: T2 or T3?
    Ucvet, Ahmet
    Yazgan, Serkan
    Sanli, Bahar Agaoglu
    Sirzai, Esra Yamansavci
    UPDATES IN SURGERY, 2023, 75 (07) : 2017 - 2025
  • [46] Treatment Selection for T3/T4a Laryngeal Cancer: Chemoradiation Versus Primary Surgery
    Timme, David W.
    Jonnalagadda, Sashikanth
    Patel, Raunak
    Rao, Krishna
    Robbins, K. Thomas
    ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 2015, 124 (11): : 845 - 851
  • [47] RADIOTHERAPY USING 3 SMALL FRACTIONS PER DAY FOR ADVANCED LARYNGEAL-CANCER
    BISSETT, D
    MORGAN, DAL
    BRADLEY, PJ
    MACLENNAN, KA
    BRITISH JOURNAL OF RADIOLOGY, 1988, 61 (728): : 713 - 713
  • [48] STUDIES ON THE DEIODINATION OF 3,3',5'-T3(REVERSE T3) TO 3,3'-T2(DIIODOTHYRONINE) IN RAT-LIVER
    HUFNER, M
    GRUSSENDORF, M
    ACTA BIOLOGICA ET MEDICA GERMANICA, 1980, 39 (2-3) : 169 - 175
  • [49] Maximal partial spreads of T2(O) and T3(O)
    Brown, MR
    De Beule, J
    Storme, L
    EUROPEAN JOURNAL OF COMBINATORICS, 2003, 24 (01) : 73 - 84
  • [50] T2 AND T3 OBJECTS AT p IN THE CATEGORY OF PROXIMITY SPACES
    Kula, Muammer
    Ozkan, Samed
    MATHEMATICA BOHEMICA, 2020, 145 (02): : 177 - 190